Senhwa raises $17m to progress ex-Cylene assets
This article was originally published in Scrip
Executive Summary
The Taiwanese oncology venture Senhwa Biosciences has raised $17m in a Series B financing that will be used to support further clinical trials for its oncology pipeline, comprising two small molecules acquired from the private US firm Cylene Pharmaceuticals.